MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

Name
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Accession Number
DBCAT005726
Description

Not Available

ATC Classification
Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or S├ęzary syndrome after attempting one other therapy.
Moxetumomab pasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
EdrecolomabNot Annotated
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
BermekimabBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
RetifanlimabNot Annotated
Trastuzumab duocarmazineTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
AmivantamabAn EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
ProlgolimabNot Annotated
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
RituximabB-lymphocyte antigen CD20target
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PanitumumabEpidermal growth factor receptortarget
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
RamucirumabVascular endothelial growth factor receptor 2target
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
OlaratumabPlatelet-derived growth factor receptor alphatarget
IpilimumabCytotoxic T-lymphocyte protein 4target
ElotuzumabSLAM family member 7target
PertuzumabReceptor tyrosine-protein kinase erbB-2target
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
OfatumumabB-lymphocyte antigen CD20target
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
ObinutuzumabB-lymphocyte antigen CD20target
NivolumabProgrammed cell death protein 1target
NivolumabProgrammed cell death 1 ligand 1target
PembrolizumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death 1 ligand 1target
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DinutuximabGD2 disialogangliosidetarget
DaratumumabADP-ribosyl cyclase 1target
NecitumumabEpidermal growth factor receptortarget
AtezolizumabProgrammed cell death 1 ligand 1target
AtezolizumabProgrammed cell death protein 1target
DurvalumabProgrammed cell death 1 ligand 1target
DurvalumabProgrammed cell death protein 1target
AvelumabProgrammed cell death 1 ligand 1target
AvelumabProgrammed cell death protein 1target
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
MogamulizumabC-C chemokine receptor type 4target
Moxetumomab pasudotoxB-cell receptor CD22target
Moxetumomab pasudotoxElongation factor 2target
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
CemiplimabProgrammed cell death protein 1target
IsatuximabADP-ribosyl cyclase 1target
TislelizumabProgrammed cell death protein 1target
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter
TafasitamabB-lymphocyte antigen CD19target
DostarlimabProgrammed cell death protein 1target
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
RetifanlimabProgrammed cell death protein 1target
AmivantamabEpidermal growth factor receptortarget
AmivantamabHepatocyte growth factor receptortarget
AmivantamabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
ProlgolimabProgrammed cell death protein 1target